SCHEMBL4196246

SCHEMBL4196246

Cc1ccccc1S(=O)(=O)NC(=O)c1ccccc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.61
CA2 P00918 5/20 0.61
CA9 Q16790 5/20 0.61
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 5/20 0.51
HPGD P15428 3/20 0.51
KAT6A Q92794 1/20 0.51
FLT1 P17948 2/20 0.50
FLT4 P35916 2/20 0.50
KDR P35968 2/20 0.50
ALKBH2 Q6NS38 1/20 0.49
ALKBH3 Q96Q83 1/20 0.49
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
LMNA P02545 1/20 0.45
CA12 O43570 2/20 0.44
HSD17B10 Q99714 3/20 0.44
CFTR P13569 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9176782 0.87 FLT1 (0.63) CA1CA2CA9KDM4EALDH1A1
SCHEMBL23918989 0.87 CA9 (0.47) CA1CA2CA9KDM4EALDH1A1
SCHEMBL28698411 0.82 FLT1 (0.60) CA1CA2CA9HPGDKAT6A
SCHEMBL28690677 0.79 CTSD (0.53) CA1CA2CA9KAT6AFLT1
SCHEMBL3637063 0.78 LMNA (0.68) CA1CA2CA9ALDH1A1HPGD
SCHEMBL4196234 0.78 KDM4E (0.68) CA1CA2CA9KDM4EALDH1A1
SCHEMBL4202292 0.77 MYC (0.55) KDM4EALDH1A1HPGDHSD17B10CFTR
SCHEMBL29489589 0.77 CA1 (0.55) CA1CA2CA9KDM4EALDH1A1
SCHEMBL6465947 0.77 CA1 (0.55) CA1CA2CA9KDM4EALDH1A1
SCHEMBL3206422 0.77 SLC1A3 (0.55) CA1CA2CA9KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
EP-1539697-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS Memory Pharmaceutical Corporation (US) 2005-06-15 EP disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed
WO-2004009552-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A CA1 4217/4885CA2 1857/4885CA9 2060/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A CA1 4217/4885CA2 1857/4885CA9 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.